{"id":348115,"date":"2025-08-25T13:58:39","date_gmt":"2025-08-25T13:58:39","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-sage-therapeutics\/"},"modified":"2025-08-25T13:58:39","modified_gmt":"2025-08-25T13:58:39","slug":"how-to-buy-sage-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/","title":{"rendered":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Sage Therapeutics (SAGE) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin, g\u00fcncel fiyat trendlerini, sat\u0131n alma etkilerini anlay\u0131n ve bu biyofarmas\u00f6tik \u015firketin hisseleri hakk\u0131nda bilin\u00e7li kararlar verin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Sage Therapeutics (SAGE) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin, g\u00fcncel fiyat trendlerini, sat\u0131n alma etkilerini anlay\u0131n ve bu biyofarmas\u00f6tik \u015firketin hisseleri hakk\u0131nda bilin\u00e7li kararlar verin."},"intro":"Zihinsel sa\u011fl\u0131k tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Sage Therapeutics (SAGE), yenilik, sat\u0131n alma ve piyasa d\u00f6n\u00fc\u015f\u00fcm\u00fc a\u00e7\u0131s\u0131ndan b\u00fcy\u00fcleyici bir hikaye sunuyor. Do\u011fum sonras\u0131 depresyon i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler ve yak\u0131n zamanda ger\u00e7ekle\u015fen b\u00fcy\u00fck bir sat\u0131n alma ile bu hisse, biyofarmas\u00f6tik sekt\u00f6r\u00fc anlamak isteyen ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in benzersiz f\u0131rsatlar sunuyor.","intro_source":{"label":"Intro","type":"text","formatted_value":"Zihinsel sa\u011fl\u0131k tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Sage Therapeutics (SAGE), yenilik, sat\u0131n alma ve piyasa d\u00f6n\u00fc\u015f\u00fcm\u00fc a\u00e7\u0131s\u0131ndan b\u00fcy\u00fcleyici bir hikaye sunuyor. Do\u011fum sonras\u0131 depresyon i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler ve yak\u0131n zamanda ger\u00e7ekle\u015fen b\u00fcy\u00fck bir sat\u0131n alma ile bu hisse, biyofarmas\u00f6tik sekt\u00f6r\u00fc anlamak isteyen ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in benzersiz f\u0131rsatlar sunuyor."},"body_html":"<h2>\ud83d\udcc8 Sage Therapeutics Hisse Senedi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Sage Therapeutics (SAGE) hisseleri <strong>8,68 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin tarihindeki kritik bir d\u00f6neme denk geliyor; yak\u0131n zamanda Supernus Pharmaceuticals taraf\u0131ndan sat\u0131n al\u0131nmas\u0131n\u0131n ard\u0131ndan.<\/p> <p><strong>Takviminize not edin: 4 Kas\u0131m 2025<\/strong>, SAGE yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirket, Supernus sahipli\u011fi alt\u0131nda bir sonraki kazan\u00e7 raporunu o tarihte a\u00e7\u0131klayacak. Tarihsel olarak, kazan\u00e7 raporlar\u0131 Sage gibi biyotek hisse senetleri i\u00e7in b\u00fcy\u00fck tetikleyiciler olmu\u015ftur.<\/p> <h3>B\u00fcy\u00fck Haber Olaylar\u0131n\u0131n SAGE Hisselerini Nas\u0131l Hareket Ettirdi\u011fi<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>30 Temmuz 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7 Raporu<\/td><td>8,95 $<\/td><td>-%3,0 (sat\u0131n alma belirsizli\u011fi)<\/td><\/tr> <tr><td>16 Haziran 2025<\/td><td>Supernus Sat\u0131n Alma Duyurusu<\/td><td>7,20 $<\/td><td>+%20,6 (anla\u015fma primi heyecan\u0131)<\/td><\/tr> <tr><td>Ocak 2025<\/td><td>Biogen Teklifinin Reddedilmesi<\/td><td>5,80 $<\/td><td>+%24,1 (daha y\u00fcksek de\u011ferleme umutlar\u0131)<\/td><\/tr> <tr><td>A\u011fustos 2023<\/td><td>Zurzuvae FDA Onay\u0131<\/td><td>15,40 $<\/td><td>+%42,8 (ilk onay co\u015fkusu)<\/td><\/tr> <tr><td>2024 Ba\u015flar\u0131<\/td><td>MDD Ba\u015fvurusunun Reddedilmesi<\/td><td>12,80 $<\/td><td>-%58,2 (b\u00fcy\u00fck gerileme)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Olumlu d\u00fczenleyici haberler genellikle \u00f6nemli fiyat s\u0131\u00e7ramalar\u0131na yol a\u00e7ar (+%20-40), gerilemeler ise dramatik d\u00fc\u015f\u00fc\u015flere neden olur. Sat\u0131n alma haberi sa\u011fl\u0131kl\u0131 bir prim sa\u011flad\u0131, ancak entegrasyonla ilgili belirsizlik son zamanlarda volatilite yaratt\u0131.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgal\u0131 \u0130yile\u015fme<\/h2> <p>Sage Therapeutics hisseleri, \u015eubat 2025'ten A\u011fustos 2025'e kadar yakla\u015f\u0131k <strong>%50<\/strong> art\u0131\u015fla dikkat \u00e7ekici bir d\u00f6n\u00fc\u015f\u00fcm ya\u015fad\u0131:<\/p> <ul> <li><strong>\u015eubat 2025<\/strong>: 5,80 $ (MDD reddi sonras\u0131 dipler, Biogen teklifinin reddi)<\/li> <li><strong>Nisan 2025<\/strong>: 6,90 $ (sat\u0131n alma spek\u00fclasyonlar\u0131n\u0131n artmas\u0131)<\/li> <li><strong>Haziran 2025<\/strong>: 8,65 $ (Supernus anla\u015fma duyurusu heyecan\u0131)<\/li> <li><strong>Temmuz 2025<\/strong>: 9,10 $ (anla\u015fma tamamlanma beklentisi)<\/li> <li><strong>A\u011fustos 2025<\/strong>: 8,68 $ (sat\u0131n alma sonras\u0131 ger\u00e7eklik kontrol\u00fc)<\/li> <\/ul> <p>Bu iyile\u015fme hikayesi, biyotek hisse senetlerinin d\u00fczenleyici gerilemelerden stratejik f\u0131rsatlar ortaya \u00e7\u0131kt\u0131\u011f\u0131nda dramatik \u015fekilde toparlanabilece\u011fini g\u00f6steriyor.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut sat\u0131n alma ko\u015fullar\u0131 ve piyasa dinamiklerine dayanarak, beklenenler \u015funlard\u0131r:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 8,50-9,00 $ (sat\u0131n alma nakit \u00f6deme seviyesi) \u2192 <strong>TUT<\/strong><\/li> <li><strong>2026<\/strong>: 3,50-12,00 $ aral\u0131\u011f\u0131 (Zurzuvae performans\u0131na ba\u011fl\u0131 ko\u015fullu de\u011fer haklar\u0131)<\/li> <li><strong>2028<\/strong>: 5,00-15,00 $ (Supernus ile uzun vadeli entegrasyon ba\u015far\u0131s\u0131)<\/li> <li><strong>2030<\/strong>: 8,00-20,00 $ (tam boru hatt\u0131 entegrasyonu ve piyasa geni\u015flemesi)<\/li> <\/ul> <p><strong>Karar<\/strong>: Sat\u0131n alma ikili bir sonu\u00e7 yarat\u0131yor - ya CVR'lar \u00f6nemli \u00f6l\u00e7\u00fcde \u00f6deme yapacak ya da yat\u0131r\u0131mc\u0131lar minimal ek de\u011fer alacak. Bu da SAGE'yi net bir al\u0131m veya sat\u0131mdan ziyade <strong>spek\u00fclatif bir tutu\u015f<\/strong> haline getiriyor.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Sat\u0131n alma entegrasyon riski<\/strong>: \u0130ki ila\u00e7 \u015firketinin birle\u015fmesi genellikle operasyonel zorluklar yarat\u0131r<\/li> <li><strong>Zurzuvae ticari belirsizli\u011fi<\/strong>: CVR \u00f6demeleri, ula\u015f\u0131lmayabilecek sat\u0131\u015f kilometre ta\u015flar\u0131na ba\u011fl\u0131d\u0131r<\/li> <li><strong>D\u00fczenleyici ba\u011f\u0131ml\u0131l\u0131k<\/strong>: Gelecekteki gelir, ba\u015far\u0131l\u0131 ila\u00e7 ticarile\u015ftirmesi ve potansiyel yeni onaylara ba\u011fl\u0131d\u0131r<\/li> <li><strong>Piyasa volatilitesi<\/strong>: Biyotek hisse senetleri genellikle k\u00f6kl\u00fc \u015firketlere g\u00f6re daha y\u00fcksek fiyat dalgalanmalar\u0131 ya\u015far<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>An\u0131nda nakit \u00f6deme<\/strong>: Hisse ba\u015f\u0131na 8,50 $ a\u015fa\u011f\u0131 y\u00f6nl\u00fc koruma sa\u011flar<\/li> <li><strong>B\u00fcy\u00fcme potansiyeli<\/strong>: Ticari hedefler kar\u015f\u0131lan\u0131rsa CVR'lar hisse ba\u015f\u0131na ek 3,50 $ sunar<\/li> <li><strong>Stratejik uyum<\/strong>: Supernus'un n\u00f6ropsikiyatri odakl\u0131 yap\u0131s\u0131 Sage'in boru hatt\u0131yla m\u00fckemmel uyum sa\u011flar<\/li> <li><strong>Maliyet sinerjileri<\/strong>: Sat\u0131n almadan y\u0131ll\u0131k 200 milyon $ tasarruf \u00f6ng\u00f6r\u00fcl\u00fcyor<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>Sat\u0131n alma yap\u0131s\u0131n\u0131 anlay\u0131n<\/strong>: Temelde iki bile\u015fen al\u0131yorsunuz - garantili 8,50 $ nakit ve spek\u00fclatif CVR'lar<\/li> <li><strong>Uygun b\u00fcy\u00fckl\u00fckte pozisyon al\u0131n<\/strong>: Bu spek\u00fclatif bir pozisyon - portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5'inden fazlas\u0131n\u0131 ay\u0131rmay\u0131n<\/li> <li><strong>Kilometre ta\u015flar\u0131n\u0131 takip edin<\/strong>: Zurzuvae re\u00e7ete verilerini ve Supernus'un \u00e7eyrek raporlar\u0131n\u0131 izleyin<\/li> <li><strong>Esprili yakla\u015f\u0131m<\/strong>: \"\u015eimdi SAGE ticareti yapmak, gizemli kutu paket yeme\u011fi sipari\u015f etmek gibi - pirinci (8,50 $) alaca\u011f\u0131n\u0131z\u0131 biliyorsunuz, ama ana yemek filet mignon ya da kalan tofu (3,50 $ CVR) olabilir\"<\/li> <\/ol>  <h2>\u2705 Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>SAGE Nasdaq'tan \u00e7\u0131kar\u0131laca\u011f\u0131 i\u00e7in OTC\/pink sheet i\u015flemi sunan bir platform se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Spek\u00fclatif do\u011fas\u0131 nedeniyle k\u00fc\u00e7\u00fck bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"SAGE\" aramas\u0131 yap\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131z\u0131 tam kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Sat\u0131n alma ko\u015fullar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td><td>Nakit ve potansiyel CVR \u00f6demeleri i\u00e7in haklar ald\u0131\u011f\u0131n\u0131z\u0131 anlay\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Sat\u0131n almay\u0131 onaylay\u0131n<\/td><td>\u00dccretleri ve takas detaylar\u0131n\u0131 iki kez kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Fiyat uyar\u0131lar\u0131 kurun<\/td><td>\u00d6nemli kilometre ta\u015f\u0131 duyurular\u0131n\u0131 takip edin<\/td><\/tr> <tr><td>8<\/td><td>Performans\u0131 izleyin<\/td><td>G\u00fcncellemeler i\u00e7in Supernus kazan\u00e7 raporlar\u0131n\u0131 takip edin<\/td><\/tr> <tr><td>9<\/td><td>Vergi etkilerini de\u011ferlendirin<\/td><td>Sat\u0131n alma benzersiz vergi muamelesi yaratabilir<\/td><\/tr> <tr><td>10<\/td><td>D\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td><td>Her kazan\u00e7 raporundan sonra pozisyonunuzu yeniden de\u011ferlendirin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Spek\u00fclatif biyotek yat\u0131r\u0131m\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong> - SAGE ile stratejileri \u00f6nemli risk olmadan test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Minimum belge gereksinimiyle h\u0131zl\u0131ca ba\u015flay\u0131n<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> - Kazan\u00e7lar\u0131 realize etmek veya pozisyonlar\u0131 ayarlamak i\u00e7in esneklik<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong> - Sat\u0131n alma arbitraj\u0131 ve \u00f6zel durum yat\u0131r\u0131m\u0131 hakk\u0131nda \u00f6\u011frenin<\/li> <\/ul>  <h2>\ud83c\udf0d 2025'te Sage Therapeutics: Sat\u0131n Alma D\u00f6n\u00fc\u015f\u00fcm\u00fc<\/h2> <p>Sage Therapeutics, A\u011fustos 2025'te tamamlanan 795 milyon $ de\u011ferindeki sat\u0131n alma sonras\u0131 art\u0131k Supernus Pharmaceuticals'\u0131n bir par\u00e7as\u0131 olarak faaliyet g\u00f6stermektedir. \u015eirket, do\u011fum sonras\u0131 depresyon i\u00e7in FDA onayl\u0131 tek iki tedavi olan Zulresso (IV form\u00fclasyon) ve Zurzuvae (oral ila\u00e7) geli\u015ftirmi\u015ftir.<\/p> <p><strong>G\u00fcncel Odak<\/strong>: Supernus'un n\u00f6ropsikiyatri portf\u00f6y\u00fcne entegrasyon, Zurzuvae ticarile\u015ftirmesinin maksimize edilmesi ve Sage'in merkezi sinir sistemi ke\u015fif platformunun gelecekteki geli\u015ftirmeler i\u00e7in kullan\u0131lmas\u0131.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Sat\u0131n alma s\u00fcrecinde, Sage'in ara\u015ft\u0131rma ekibi ofis bitkilerinin \u00e7al\u0131\u015fanlar taraf\u0131ndan \u00e7e\u015fitli n\u00f6rotransmitterlerin isimleriyle adland\u0131r\u0131ld\u0131\u011f\u0131n\u0131 ke\u015ffetti - \"Serotonin Sally\" ve \"Dopamine Dave\" biyotek sosyal medya \u00e7evrelerinde k\u00fc\u00e7\u00fck \u00fcnl\u00fcler haline geldi!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Sage Therapeutics Hisse Senedi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Sage Therapeutics (SAGE) hisseleri <strong>8,68 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin tarihindeki kritik bir d\u00f6neme denk geliyor; yak\u0131n zamanda Supernus Pharmaceuticals taraf\u0131ndan sat\u0131n al\u0131nmas\u0131n\u0131n ard\u0131ndan.<\/p>\n<p><strong>Takviminize not edin: 4 Kas\u0131m 2025<\/strong>, SAGE yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirket, Supernus sahipli\u011fi alt\u0131nda bir sonraki kazan\u00e7 raporunu o tarihte a\u00e7\u0131klayacak. Tarihsel olarak, kazan\u00e7 raporlar\u0131 Sage gibi biyotek hisse senetleri i\u00e7in b\u00fcy\u00fck tetikleyiciler olmu\u015ftur.<\/p>\n<h3>B\u00fcy\u00fck Haber Olaylar\u0131n\u0131n SAGE Hisselerini Nas\u0131l Hareket Ettirdi\u011fi<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>30 Temmuz 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7 Raporu<\/td>\n<td>8,95 $<\/td>\n<td>-%3,0 (sat\u0131n alma belirsizli\u011fi)<\/td>\n<\/tr>\n<tr>\n<td>16 Haziran 2025<\/td>\n<td>Supernus Sat\u0131n Alma Duyurusu<\/td>\n<td>7,20 $<\/td>\n<td>+%20,6 (anla\u015fma primi heyecan\u0131)<\/td>\n<\/tr>\n<tr>\n<td>Ocak 2025<\/td>\n<td>Biogen Teklifinin Reddedilmesi<\/td>\n<td>5,80 $<\/td>\n<td>+%24,1 (daha y\u00fcksek de\u011ferleme umutlar\u0131)<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2023<\/td>\n<td>Zurzuvae FDA Onay\u0131<\/td>\n<td>15,40 $<\/td>\n<td>+%42,8 (ilk onay co\u015fkusu)<\/td>\n<\/tr>\n<tr>\n<td>2024 Ba\u015flar\u0131<\/td>\n<td>MDD Ba\u015fvurusunun Reddedilmesi<\/td>\n<td>12,80 $<\/td>\n<td>-%58,2 (b\u00fcy\u00fck gerileme)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Olumlu d\u00fczenleyici haberler genellikle \u00f6nemli fiyat s\u0131\u00e7ramalar\u0131na yol a\u00e7ar (+%20-40), gerilemeler ise dramatik d\u00fc\u015f\u00fc\u015flere neden olur. Sat\u0131n alma haberi sa\u011fl\u0131kl\u0131 bir prim sa\u011flad\u0131, ancak entegrasyonla ilgili belirsizlik son zamanlarda volatilite yaratt\u0131.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgal\u0131 \u0130yile\u015fme<\/h2>\n<p>Sage Therapeutics hisseleri, \u015eubat 2025&#8217;ten A\u011fustos 2025&#8217;e kadar yakla\u015f\u0131k <strong>%50<\/strong> art\u0131\u015fla dikkat \u00e7ekici bir d\u00f6n\u00fc\u015f\u00fcm ya\u015fad\u0131:<\/p>\n<ul>\n<li><strong>\u015eubat 2025<\/strong>: 5,80 $ (MDD reddi sonras\u0131 dipler, Biogen teklifinin reddi)<\/li>\n<li><strong>Nisan 2025<\/strong>: 6,90 $ (sat\u0131n alma spek\u00fclasyonlar\u0131n\u0131n artmas\u0131)<\/li>\n<li><strong>Haziran 2025<\/strong>: 8,65 $ (Supernus anla\u015fma duyurusu heyecan\u0131)<\/li>\n<li><strong>Temmuz 2025<\/strong>: 9,10 $ (anla\u015fma tamamlanma beklentisi)<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 8,68 $ (sat\u0131n alma sonras\u0131 ger\u00e7eklik kontrol\u00fc)<\/li>\n<\/ul>\n<p>Bu iyile\u015fme hikayesi, biyotek hisse senetlerinin d\u00fczenleyici gerilemelerden stratejik f\u0131rsatlar ortaya \u00e7\u0131kt\u0131\u011f\u0131nda dramatik \u015fekilde toparlanabilece\u011fini g\u00f6steriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut sat\u0131n alma ko\u015fullar\u0131 ve piyasa dinamiklerine dayanarak, beklenenler \u015funlard\u0131r:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 8,50-9,00 $ (sat\u0131n alma nakit \u00f6deme seviyesi) \u2192 <strong>TUT<\/strong><\/li>\n<li><strong>2026<\/strong>: 3,50-12,00 $ aral\u0131\u011f\u0131 (Zurzuvae performans\u0131na ba\u011fl\u0131 ko\u015fullu de\u011fer haklar\u0131)<\/li>\n<li><strong>2028<\/strong>: 5,00-15,00 $ (Supernus ile uzun vadeli entegrasyon ba\u015far\u0131s\u0131)<\/li>\n<li><strong>2030<\/strong>: 8,00-20,00 $ (tam boru hatt\u0131 entegrasyonu ve piyasa geni\u015flemesi)<\/li>\n<\/ul>\n<p><strong>Karar<\/strong>: Sat\u0131n alma ikili bir sonu\u00e7 yarat\u0131yor &#8211; ya CVR&#8217;lar \u00f6nemli \u00f6l\u00e7\u00fcde \u00f6deme yapacak ya da yat\u0131r\u0131mc\u0131lar minimal ek de\u011fer alacak. Bu da SAGE&#8217;yi net bir al\u0131m veya sat\u0131mdan ziyade <strong>spek\u00fclatif bir tutu\u015f<\/strong> haline getiriyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Sat\u0131n alma entegrasyon riski<\/strong>: \u0130ki ila\u00e7 \u015firketinin birle\u015fmesi genellikle operasyonel zorluklar yarat\u0131r<\/li>\n<li><strong>Zurzuvae ticari belirsizli\u011fi<\/strong>: CVR \u00f6demeleri, ula\u015f\u0131lmayabilecek sat\u0131\u015f kilometre ta\u015flar\u0131na ba\u011fl\u0131d\u0131r<\/li>\n<li><strong>D\u00fczenleyici ba\u011f\u0131ml\u0131l\u0131k<\/strong>: Gelecekteki gelir, ba\u015far\u0131l\u0131 ila\u00e7 ticarile\u015ftirmesi ve potansiyel yeni onaylara ba\u011fl\u0131d\u0131r<\/li>\n<li><strong>Piyasa volatilitesi<\/strong>: Biyotek hisse senetleri genellikle k\u00f6kl\u00fc \u015firketlere g\u00f6re daha y\u00fcksek fiyat dalgalanmalar\u0131 ya\u015far<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>An\u0131nda nakit \u00f6deme<\/strong>: Hisse ba\u015f\u0131na 8,50 $ a\u015fa\u011f\u0131 y\u00f6nl\u00fc koruma sa\u011flar<\/li>\n<li><strong>B\u00fcy\u00fcme potansiyeli<\/strong>: Ticari hedefler kar\u015f\u0131lan\u0131rsa CVR&#8217;lar hisse ba\u015f\u0131na ek 3,50 $ sunar<\/li>\n<li><strong>Stratejik uyum<\/strong>: Supernus&#8217;un n\u00f6ropsikiyatri odakl\u0131 yap\u0131s\u0131 Sage&#8217;in boru hatt\u0131yla m\u00fckemmel uyum sa\u011flar<\/li>\n<li><strong>Maliyet sinerjileri<\/strong>: Sat\u0131n almadan y\u0131ll\u0131k 200 milyon $ tasarruf \u00f6ng\u00f6r\u00fcl\u00fcyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>Sat\u0131n alma yap\u0131s\u0131n\u0131 anlay\u0131n<\/strong>: Temelde iki bile\u015fen al\u0131yorsunuz &#8211; garantili 8,50 $ nakit ve spek\u00fclatif CVR&#8217;lar<\/li>\n<li><strong>Uygun b\u00fcy\u00fckl\u00fckte pozisyon al\u0131n<\/strong>: Bu spek\u00fclatif bir pozisyon &#8211; portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5&#8217;inden fazlas\u0131n\u0131 ay\u0131rmay\u0131n<\/li>\n<li><strong>Kilometre ta\u015flar\u0131n\u0131 takip edin<\/strong>: Zurzuvae re\u00e7ete verilerini ve Supernus&#8217;un \u00e7eyrek raporlar\u0131n\u0131 izleyin<\/li>\n<li><strong>Esprili yakla\u015f\u0131m<\/strong>: &#8220;\u015eimdi SAGE ticareti yapmak, gizemli kutu paket yeme\u011fi sipari\u015f etmek gibi &#8211; pirinci (8,50 $) alaca\u011f\u0131n\u0131z\u0131 biliyorsunuz, ama ana yemek filet mignon ya da kalan tofu (3,50 $ CVR) olabilir&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>SAGE Nasdaq&#8217;tan \u00e7\u0131kar\u0131laca\u011f\u0131 i\u00e7in OTC\/pink sheet i\u015flemi sunan bir platform se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Spek\u00fclatif do\u011fas\u0131 nedeniyle k\u00fc\u00e7\u00fck bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;SAGE&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 tam kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sat\u0131n alma ko\u015fullar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td>\n<td>Nakit ve potansiyel CVR \u00f6demeleri i\u00e7in haklar ald\u0131\u011f\u0131n\u0131z\u0131 anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Sat\u0131n almay\u0131 onaylay\u0131n<\/td>\n<td>\u00dccretleri ve takas detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>\u00d6nemli kilometre ta\u015f\u0131 duyurular\u0131n\u0131 takip edin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Performans\u0131 izleyin<\/td>\n<td>G\u00fcncellemeler i\u00e7in Supernus kazan\u00e7 raporlar\u0131n\u0131 takip edin<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Vergi etkilerini de\u011ferlendirin<\/td>\n<td>Sat\u0131n alma benzersiz vergi muamelesi yaratabilir<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>D\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td>\n<td>Her kazan\u00e7 raporundan sonra pozisyonunuzu yeniden de\u011ferlendirin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Spek\u00fclatif biyotek yat\u0131r\u0131m\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong> &#8211; SAGE ile stratejileri \u00f6nemli risk olmadan test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Minimum belge gereksinimiyle h\u0131zl\u0131ca ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> &#8211; Kazan\u00e7lar\u0131 realize etmek veya pozisyonlar\u0131 ayarlamak i\u00e7in esneklik<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong> &#8211; Sat\u0131n alma arbitraj\u0131 ve \u00f6zel durum yat\u0131r\u0131m\u0131 hakk\u0131nda \u00f6\u011frenin<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Sage Therapeutics: Sat\u0131n Alma D\u00f6n\u00fc\u015f\u00fcm\u00fc<\/h2>\n<p>Sage Therapeutics, A\u011fustos 2025&#8217;te tamamlanan 795 milyon $ de\u011ferindeki sat\u0131n alma sonras\u0131 art\u0131k Supernus Pharmaceuticals&#8217;\u0131n bir par\u00e7as\u0131 olarak faaliyet g\u00f6stermektedir. \u015eirket, do\u011fum sonras\u0131 depresyon i\u00e7in FDA onayl\u0131 tek iki tedavi olan Zulresso (IV form\u00fclasyon) ve Zurzuvae (oral ila\u00e7) geli\u015ftirmi\u015ftir.<\/p>\n<p><strong>G\u00fcncel Odak<\/strong>: Supernus&#8217;un n\u00f6ropsikiyatri portf\u00f6y\u00fcne entegrasyon, Zurzuvae ticarile\u015ftirmesinin maksimize edilmesi ve Sage&#8217;in merkezi sinir sistemi ke\u015fif platformunun gelecekteki geli\u015ftirmeler i\u00e7in kullan\u0131lmas\u0131.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Sat\u0131n alma s\u00fcrecinde, Sage&#8217;in ara\u015ft\u0131rma ekibi ofis bitkilerinin \u00e7al\u0131\u015fanlar taraf\u0131ndan \u00e7e\u015fitli n\u00f6rotransmitterlerin isimleriyle adland\u0131r\u0131ld\u0131\u011f\u0131n\u0131 ke\u015ffetti &#8211; &#8220;Serotonin Sally&#8221; ve &#8220;Dopamine Dave&#8221; biyotek sosyal medya \u00e7evrelerinde k\u00fc\u00e7\u00fck \u00fcnl\u00fcler haline geldi!<\/p>\n"},"faq":[{"question":"Sage Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir OTC\/pink sheet ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"SAGE\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin ve sat\u0131n alma ko\u015fullar\u0131n\u0131 dikkatlice inceleyin."},{"question":"SAGE hisselerinin fiyat\u0131 ne kadar?","answer":"25 A\u011fustos 2025 itibar\u0131yla SAGE hisseleri 8,68 $ seviyesinde i\u015flem g\u00f6rmektedir."},{"question":"Sat\u0131n alma sonras\u0131 SAGE hisseleri i\u00e7in beklentiler nelerdir?","answer":"2025 sonunda 8,50-9,00 $ aral\u0131\u011f\u0131nda tutma \u00f6nerilir; 2026 ve sonras\u0131 i\u00e7in CVR performans\u0131na ba\u011fl\u0131 olarak 3,50-20,00 $ aras\u0131nda de\u011fi\u015fen fiyat tahminleri vard\u0131r."},{"question":"SAGE hisseleri i\u00e7in temel riskler nelerdir?","answer":"Sat\u0131n alma entegrasyon riski, Zurzuvae'nin ticari ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, d\u00fczenleyici ba\u011f\u0131ml\u0131l\u0131k ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar SAGE hisseleriyle ilgili ne yapmal\u0131?","answer":"Sat\u0131n alma yap\u0131s\u0131n\u0131 anlay\u0131n, portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle pozisyon al\u0131n, \u00f6nemli kilometre ta\u015flar\u0131n\u0131 takip edin ve d\u00fczenli olarak pozisyonunuzu g\u00f6zden ge\u00e7irin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Sage Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir OTC\/pink sheet ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"SAGE\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak sat\u0131n alma i\u015flemini ger\u00e7ekle\u015ftirin ve sat\u0131n alma ko\u015fullar\u0131n\u0131 dikkatlice inceleyin."},{"question":"SAGE hisselerinin fiyat\u0131 ne kadar?","answer":"25 A\u011fustos 2025 itibar\u0131yla SAGE hisseleri 8,68 $ seviyesinde i\u015flem g\u00f6rmektedir."},{"question":"Sat\u0131n alma sonras\u0131 SAGE hisseleri i\u00e7in beklentiler nelerdir?","answer":"2025 sonunda 8,50-9,00 $ aral\u0131\u011f\u0131nda tutma \u00f6nerilir; 2026 ve sonras\u0131 i\u00e7in CVR performans\u0131na ba\u011fl\u0131 olarak 3,50-20,00 $ aras\u0131nda de\u011fi\u015fen fiyat tahminleri vard\u0131r."},{"question":"SAGE hisseleri i\u00e7in temel riskler nelerdir?","answer":"Sat\u0131n alma entegrasyon riski, Zurzuvae'nin ticari ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, d\u00fczenleyici ba\u011f\u0131ml\u0131l\u0131k ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar SAGE hisseleriyle ilgili ne yapmal\u0131?","answer":"Sat\u0131n alma yap\u0131s\u0131n\u0131 anlay\u0131n, portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle pozisyon al\u0131n, \u00f6nemli kilometre ta\u015flar\u0131n\u0131 takip edin ve d\u00fczenli olarak pozisyonunuzu g\u00f6zden ge\u00e7irin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T13:58:39+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T13:58:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/\",\"name\":\"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-25T13:58:39+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T13:58:39+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T13:58:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/","name":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-25T13:58:39+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":348110,"slug":"how-to-buy-sage-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Sage Therapeutics, Inc. (SAGE) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":348109,"slug":"how-to-buy-sage-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Sage Therapeutics, Inc. (SAGE) - Investimento em a\u00e7\u00f5es da Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-sage-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=348115"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348115\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=348115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=348115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=348115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}